By Cole Bunn, Research Analyst, LSN
The diagnostics space encompasses a very wide range of technologies targeting indications across the board, and is arguably the most difficult sector, under the life science umbrella, to successfully navigate. Not only do these entrepreneurs have to first identify the correct capital providers and strategic partners to make their technologies a commercial reality, like everyone else, but piquing the interests of those entities may be considerably more difficult. Oftentimes, clearly articulating the value proposition of your diagnostic product/service is a little trickier than that of a more traditional therapeutic or medical device, and the go-to-market strategy for these technologies will usually be more highly scrutinized.
Moderated by John Walter, CEO & President, Alliance for Cancer Gene Therapy Foundation, this session will feature:
- Wouter Meuleman, Director, Corporate & Venture Development, Illumina
- Caroline Popper, President, BCM Technologies
- Tom Miller, Managing Partner, Greybird Ventures
- Tom Hawes, Managing Director, Sandbox Industries
Given the complex strategic landscape diagnostics often face, along with the importance of the having the correct strategy in place, the value of guidance and feedback from experienced diagnostic investors can’t be overstated. This diverse set of panelists, representing a variety of different funds and organizations, will give the audience firsthand perspectives to help position their companies for success.
Registering for the RESI Conference will give you the opportunity to listen to this panel live, connect with relevant investors and network with like-minded entrepreneurs.